OrSense

Company Overview

Snapshot

Founded in October 1996, OrSense operates with 11–50 employees and has raised a total of $44.4 million across six funding rounds. In May 2019, the company received FDA market clearance for its NBM200, the first noninvasive hemoglobin system approved for use in blood donation centers.

Business overview

OrSense is a medical device company specializing in the development and commercialization of noninvasive monitoring technologies. The company's core offering includes continuous and spot measurements of critical blood parameters such as hemoglobin, oxygen saturation, and glucose. Leveraging its patented SpectOLight technology, which utilizes occlusion spectroscopy with a finger-attached, ring-shaped sensor probe, OrSense serves the healthcare industry by providing high signal-to-noise ratio measurements for various medical applications, including pulse rate and oxymetry.

Strategic signal

In May 2019, OrSense secured FDA market clearance for its NBM200, marking a significant milestone as the first noninvasive hemoglobin system cleared for use in blood donation centers. This regulatory approval validates the efficacy and safety of OrSense's SpectOLight technology, positioning the company to potentially transform blood screening processes by offering a less invasive and more efficient method for hemoglobin measurement. For investors, this signals strong market readiness and a clear path to commercialization within a critical segment of the healthcare sector.

Company Intelligence Q&A

What is OrSense's core technology?

OrSense's core technology is patented SpectOLight, which employs occlusion spectroscopy. This non-invasive optical measurement platform uses a finger-attached, ring-shaped sensor probe to temporarily occlude blood flow, generating a unique optical signal for precise blood parameter analysis.

When did OrSense receive FDA clearance for its NBM200 device?

In May 2019, OrSense received FDA market clearance for its NBM200, making it the first noninvasive hemoglobin system approved for use in blood donation centers.

Has OrSense expanded its market reach internationally?

Yes, in October 2014, OrSense delivered its first systems in Mexico, indicating an expansion into international markets.

Which investors participated in OrSense's funding round in May 2011?

In May 2011, OrSense received funding from Lewis Trust Group and Israel HealthCare Ventures.

What was a key funding event for OrSense in February 2006?

In February 2006, OrSense completed a private financing round, with participation from Lewis Trust Group.